

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHERVON 泉峰®

Chervon Holdings Limited

泉峰控股有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2285)

**(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
(2) CHANGE OF COMPOSITION OF COMMITTEES OF THE BOARD
AND
(3) RE-COMPLIANCE WITH THE LISTING RULES**

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Chervon Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the appointment of Dr. Fan Hao (“**Dr. Fan**”) as an independent non-executive Director, the chairman of the remuneration committee and a member of the audit committee and the nomination committee with effect from February 4, 2026.

Dr. Fan, aged 54, has over 20 years of experience in the precision instrumentation industry. He has been the chairman of MLOptic Corp. (南京茂萊光學科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688502), since May 2015. He has also served as the general manager of Moonlight (Nanjing) Instrument Ltd.* (茂萊(南京)儀器有限公司), a subsidiary of MLOptic Corp., since June 2004. He was a director of Nanjing MLOptic Co., Ltd.* (南京茂萊光電有限公司), the predecessor company of MLOptic Corp., from December 2011 to May 2015. Prior to that, Dr. Fan served as a project manager at SCHOTT (Shanghai) Precision Materials & Equipment International Trading Co., Ltd.* (肖特(上海)精密材料和設備國際貿易有限公司) from January 2003 to May 2004, and served as a business manager at Jiangsu Provincial Foreign Trade Corporation* (江蘇省對外經貿股份有限公司) from August 1994 to December 2001.

Dr. Fan graduated from China Europe International Business School with a master’s degree in business administration in 2003 and obtained a doctoral degree in business administration from Durham University in the United Kingdom in 2020.

Dr. Fan has entered into an appointment letter with the Company. The initial term of the appointment of Dr. Fan shall be three years from his appointment subject to retirement as and when required under the Articles of Association of the Company and the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (including at the upcoming annual general meeting of the Company) and termination in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months’ prior notice in writing. Dr. Fan is entitled to receive an annual Director’s fee of RMB200,000, which was determined on the recommendation of the remuneration committee of the Board and his qualification, experience, position and responsibilities in the Company and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. Fan (i) did not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years prior to the date of this announcement; (ii) does not hold any other position with the Company or other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as respectively defined under the Listing Rules) of the Company; and (iv) does not have or is not deemed to have any interests or short positions in the shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Dr. Fan has confirmed that (a) he has satisfied all the criteria for independence as set out in Rule 3.13(1) to (8) of the Listing Rules; (b) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (c) there are no other factors that may affect his independence at the time of his appointment. Save as disclosed above, the Company is not aware of any matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to the appointment of Dr. Fan, and there is no other information relating to Dr. Fan which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

The Board would like to express its warm welcome to Dr. Fan on his new appointment.

CHANGE OF COMPOSITION OF COMMITTEES OF THE BOARD

With effect from February 4, 2026, Dr. Fan has been appointed as the chairman of the remuneration committee and a member of the audit committee and the nomination committee.

RE-COMPLIANCE WITH THE LISTING RULES

Reference is made to the announcement of the Company dated November 28, 2025. Following the appointment of Dr. Fan as an independent non-executive Director and the aforementioned changes to the composition of the Board committees, the Company has re-complied with the requirements under (i) Rules 3.10(1) and 3.10A (in respect of having at least three independent non-executive Directors representing at least one-third of the Board); (ii) Rules 3.21 (in respect of the audit committee having at least three members and comprising a majority of independent non-executive Directors), Rule 3.25 (in respect of the remuneration committee having an independent non-executive Director as chairman and comprising a majority of independent non-executive Directors); and Rule 3.27A (in respect of the nomination committee comprising a majority of independent non-executive Directors).

By order of the Board
Chervon Holdings Limited
PAN Longquan
Chairman

Hong Kong, February 4, 2026

As at the date of this announcement, the Board comprises Mr. PAN Longquan, Ms. ZHANG Tong, Mr. KE Zuqian and Mr. Michael John CLANCY as executive Directors; and Dr. LI Minghui, Mr. JIANG Li and Dr. FAN Hao as independent non-executive Directors.

* *For identification purpose only*